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Statins are inhibitors of 3-hydroxy 3-methylglutaryl
coenzyme A (HMG-CoA) reductase, the rate-limiting
enzyme in cholesterol biosynthesis. Recent clinico-
epidemiologic studies correlate patients receiving
statin therapy with having reduced mortality associ-
ated with severe bacterial infection. Investigating
the effect of statins on the innate immune capacity
of phagocytic cells against the human pathogen
Staphylococcus aureus, we uncovered a beneficial
effect of statins on bacterial clearance by phago-
cytes, although, paradoxically, both phagocytosis
and oxidative burst were inhibited. Probing instead
for an extracellular mechanism of killing, we found
that statins boosted the production of antibacterial
DNA-based extracellular traps (ETs) by human and
murine neutrophils and also monocytes/macro-
phages. The effect of statins to induce phagocyte
ETs was linked to sterol pathway inhibition. We
conclude that a drug therapy taken chronically by
millions alters the functional behavior of phagocytic
cells, which could have ramifications for suscepti-
bility and response to bacterial infections in these
patients.
INTRODUCTION
Statins are inhibitors of 3-hydroxy 3-methylglutaryl coenzyme A
(HMG-CoA) reductase, the rate-limiting enzyme in cholesterol
biosynthesis. The mainstay of current hyperlipidemia treatment,
an estimated 30 million individuals were prescribed statins in
2005 in the U.S. alone (Stagnitti, 2008.). The prevalence of statin
usage has stimulated great interest in identifying and under-Cell Host &standing significant biological effects of these drugs beyond
cholesterol lowering (Merx and Weber, 2008). One remarkable
observation to emerge from several clinico-epidemiological
studies is that patients receiving statin therapy may experience
reduced infection-associated mortality due to pneumonia
(Thomsen et al., 2008), bacteremia (Kruger et al., 2006; Liappis
et al., 2001), or sepsis (Almog et al., 2007; Kopterides and
Falagas, 2009; Martin et al., 2007). Consistent with this finding,
statin therapy improved survival in mouse sepsis models,
including lipopolysaccharide (LPS) administration (Ando et al.,
2000), cecal ligation and perforation (CLP) (Merx et al., 2004,
2005), and systemic challenge with Gram-positive or Gram-
negative bacteria (Catron et al., 2004; Chaudhry et al., 2008).
The mechanism(s) by which statin treatment may protect
against lethal bacteremia and sepsis are not yet understood.
Certain statins exhibit modest inhibitory activity against bacterial
growth in vitro, e.g., minimum inhibitory concentration (MIC)
30 mg/l versus Staphylococcus aureus for simvastatin (Jerwood
and Cohen, 2008), but the drug level required for this effect
(30mg/l = 70 mM) exceeds by300-fold the serum level reported
in the experimental mouse model following high-dose therapy
(220 nM with 100 mg/kg/day simvastatin orally) (Thelen et al.,
2006). Rather,more attention has focused on immunomodulatory
effects of statins that could reduce the proinflammatory ‘‘cytokine
storm’’ of sepsis. Statin-treated mice had decreased TNF-a and
IL-1b or IL-6 levels upon LPS challenge (Ando et al., 2000;
Chaudhry et al., 2008), and statin-treated human volunteers
receiving LPS also had lower serum TNF-a and IL-1b levels,
coupled with diminished monocyte Toll-like receptor 4 (TLR4)
and TLR2 expression (Niessner et al., 2006). Peripheral blood
mononuclear cells (PBMCs) isolated from statin-treated humans
showed diminished TNF-a and IL-6 responses to LPS ex vivo
(Rosensonet al., 1999), andstatin exposure blunted LPS-induced
TNF-a, IL-1b, IL-6, and inducible nitric oxide synthase (iNOS)
expression by rat macrophages in vitro (Pahan et al., 1997).
Here, we consider an alternative mechanism by which statins
could influence the outcome of bacterial infection: by altering theMicrobe 8, 445–454, November 18, 2010 ª2010 Elsevier Inc. 445
Figure 1. Statin Induction of Phagocyte
Antimicrobial Activity In Vitro
(A) In vitro killing of S. aureus by primary human
neutrophils or RAW 264.7 and human U937 cells
treated with mevastatin or vehicle control.
(B) Growth of S. aureus strain Newman in RPMI
with or without mevastatin (50 mM) or DMSO
vehicle control.
(C) In vitro killing of S. aureus pretreated with me-
vastatin or vehicle control by primary human
neutrophils.
(D) In vitro killing of opsonized versus nonopson-
ized S. aureus by primary human neutrophils
treated with mevastatin or vehicle control.
(E) In vitro killing of S. aureus strain Newman,
S. aureus strain Sanger (MRSA), S. agalactiae
strain COH1 (GBS), S. typhimurium, and Strepto-
coccus pneumoniae strain D39 by RAW 264.7
cells treated with mevastatin or vehicle control.
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cells. We find that statin therapy in vitro, ex vivo, and in vivo
increases the ability of phagocytes to kill the leading human
pathogen S. aureus, a phenotype we correlate to increased
production of antimicrobial DNA-based extracellular traps
(ETs). This alteration in immune cell behavior is mediated by inhi-
bition of the sterol pathway.
RESULTS
Statin Induction of Phagocyte Antimicrobial Activity
In Vitro
We first tested the effect of in vitro stimulation with the classical
HMG-CoA reductase inhibitor mevastatin on the ability of
various phagocytic cell types to kill S. aureus. Statin pretreat-
ment significantly increased the antistaphylococcal activity of
human neutrophils, human U937 monocytes/macrophages,
andmurine RAW264.7macrophages (Figure 1A). At the concen-
tration used, mevastatin had no direct effect on S. aureus growth
(Figure 1B), nor did pretreatment of S. aureus with mevastatin(C) Extracellular killing of S. aureus by primary human neutrophils treated with mev
was added to the samples 10min prior to infection. Experiments were performed 3
***p < 0.005, n.s. = not significant by two-tailed Student’s t test comparing contro
446 Cell Host & Microbe 8, 445–454, November 18, 2010 ª2010 Elserender the bacterium more susceptible to killing by normal
neutrophils (Figure 1C). Statin enhancement of human neutrophil
killing of S. aureus was observed in assays performed with or
without prior opsonization of the bacteria using autologous
serum (Figure 1D). Statin treatment enhanced RAW 264.7
macrophage clearance of strains of methicillin-resistant S.
aureus (MRSA), group B Streptococcus, Salmonella typhimu-
rium, and Streptococcus pneumoniae, suggesting the induction
of a generalized mechanism(s) for bacterial killing (Figure 1E).
In beginning to probe the mechanism by which statin treat-
ment could enhance leukocyte bactericidal function, we were
presented with a paradox. Previous literature suggested that
statin treatment of neutrophils and macrophages was associ-
ated with reduction in phagocytosis and oxidative burst, two
key effectors of bacterial killing (Benati et al., 2010; Bokoch
and Prossnitz, 1992). We confirmed that mevastatin treatment
reduced phagocytic uptake of fluorescently labeled S. aureus
by human neutrophils as measured by FACS (Figure 2A) and
reduced the magnitude of the neutrophil oxidative burst elicited
by S. aureus infection (Figure 2B). These observed inhibitoryFigure 2. Statin Treatment Reduces Phago-
cytosis and Oxidative Burst While
Increasing Extracellular Killing of S. aureus
(A) Mean fluorescence intensity as parameter for
phagocytosis of neutrophils after infection with
FITC-labeled S. aureus wood strain bioparticles
measured by flow cytometry. As a control, 10 mg/ml
of cytochalasin D was added to the samples 10 min
prior to infection to prevent phagocytosis.
(B) Oxidative burst of primary human neutrophils
stimulated with mevastatin or vehicle control
measured by flow cytometry after 30 min incuba-
tion in the presence of 20,70-dichlorofluorescein.
astatin or vehicle control. To prevent phagocytosis, 10 mg/ml of cytochalasin D
–4 times with similar results; representative experiment shown ± SD. **p < 0.01,
l versus statin-treated group.
vier Inc.
Figure 3. Statin Induction of Neutrophil
Extracellular Traps
(A) Representative fluorescent images of neutro-
phils stimulated with mevastatin or vehicle control
and PMA to induce NETs. NET formationwas visu-
alized in blue (DAPI) and LL-37 expression was
visualized by Alexa red immunostaining.
(B) NET formation was visualized in blue (DAPI)
and H2A-H2B-DNA complexes were visualized
by Alexa green immunostaining.
(C) Quantification of NET production by primary
human neutrophils ± stimulation with PMA and
treatment with mevastatin or vehicle control.
(D) Entrapment of fluorescently labeled S. aureus
by PMA-stimulated human neutrophils treated
with mevastatin or vehicle control. In (C) and (D),
***p < 0.005 by two-tailed Student’s t test
comparing control versus statin-treated group.
(E) Quantification of NET production by primary
human neutrophils ± stimulation with PMA and
treatment with different statins (MEV, mevastatin;
LOV, lovastatin; SIMV, simvastatin; FLUV, fluvas-
tatin) or vehicle control (CTRL). ***p < 0.005 by
one-way ANOVA with Dunnett’s post test versus
control group.
(F) NET production of PMA-stimulated human neutrophils treated with 10 mg/ml DPI or vehicle control to inhibit the NADPH-oxidase-dependent ROS production.
***p < 0.005 or n.s. = not significant by two-tailed Student’s t test comparing control versus statin-treated group. Experiments were performed 3–4 times with
similar results, representative experiment shown ± SD. See also Figures S1 and S2.
Cell Host & Microbe
Statins Boost Phagocyte Extracellular Trapseffects on phagocytosis and oxidative burst suggested statin
treatment was stimulating a mechanism for extracellular bacte-
rial killing. Consistent with this hypothesis, we found that
enhanced killing of S. aureus by statin-treated neutrophils was
maintained in the face of treatment with cytochalasin D (Fig-
ure 2C), an actin microfilament inhibitor that blocks bacterial
uptake (Figure 2A).
Statin Induction of Neutrophil Extracellular Traps
A key emerging concept in neutrophil biology is antimicrobial
activity achieved through the elaboration of neutrophil extracel-
lular traps (NETs) (Brinkmann et al., 2004). The product of a cell
death pathway, NETs are composed of nuclear DNA, histones,
antimicrobial peptides, and proteases and are capable of
entrapping and killing a wide variety of bacteria and other
microbes (Brinkmann and Zychlinsky, 2007; von Ko¨ckritz-Blick-
wede and Nizet, 2009). We found that mevastatin treatment
in vitro strikingly enhanced NET production by freshly isolated
and PMA-stimulated human neutrophils (Figures 3A and 3B).
Histones and cathelicidin antimicrobial peptide LL-37, two of
the key antimicrobial effectors present in NETs (Brinkmann and
Zychlinsky, 2007; von Ko¨ckritz-Blickwede and Nizet, 2009),
were also released in greater amounts following statin treatment
and colocalized within the NETs (Figures 3A and 3B). Quantifying
NETs by direct assessment of extracellular DNA release (Fuchs
et al., 2007), we calculated mevastatin-treated neutrophils
produced 2.5-fold more NETs (Figure 3C), leading to greater
entrapment of fluorescently labeled S. aureuswithin these struc-
tures (Figure 3D). We found that lovastatin, simvastatin, and flu-
vastatin also enhanced NET production, demonstrating that this
phenomenon is not limited to mevastatin and is common across
the statin class of drugs (Figure 3E). Consistent with a specific
NET-dependent killing mechanism, the mevastatin-inducedCell Host &enhancement of neutrophil bacterial killing was abrogated if
neutrophils were lysed mechanically using sonication (Fig-
ure S1A) or if exogenous micrococcal nuclease treatment was
used to degrade NETs (Figure S1B).
NET release has previously been reported to depend upon
reactive oxygen species (ROS) generation through the NAPDH
oxidase. When we blocked neutrophil ROS production using
the NADPH oxidase inhibitor diphenylene iodonium (DPI), the
level of NET generation was clearly reduced, yet still significantly
greater in statin-treated cells versus controls (Figure 3F).
Combined with the observation that statin treatment reduced
overall ROS production in the neutrophils (Figure 2B), the
evidence suggests that statins may predispose cells to enter
the NET cell death pathway in response to a lower threshold
level of ROS signal. Another biochemical marker of NET forma-
tion identified in response to LPS or ROS is deimination of
arginine residues in histones to citrullines, a posttranslational
modification catalyzed by peptidyl arginine deaminase 4
(PAD-4) that facilitates chromatin decondensation (Wang
et al., 2009). However, we found that in contrast to control
neutrophils, treatment with an inhibitor of PAD-4-mediated
histone citrullination failed to block the increased NET produc-
tion associated with mevastatin or simvastatin treatment
(Figures S2A and S2B).
Statin Induction of Macrophage Extracellular Traps
Statin enhancement of S. aureus killing was not restricted to
human neutrophils, but was also observed in monocytes/
macrophages (Figure 1A). Similar to our findings with neutro-
phils, statin treatment of RAW 264.7 macrophages reduced
phagocytic uptake of S. aureus (Figure S3). Unlike neutrophils,
eosinophils, or mast cells (von Ko¨ckritz-Blickwede et al.,
2008), release of nuclear DNA to form ETs has never beenMicrobe 8, 445–454, November 18, 2010 ª2010 Elsevier Inc. 447
Figure 4. Statin-Induced Formation of
Macrophage Extracellular Traps
(A) MET formation by RAW 264.7 cells. Represen-
tative fluorescent image of MET formation visual-
ized using blue (DAPI) and Alexa Green immunos-
taining for H2A-H2B-DNA complexes;
quantification of MET production by RAW 264.7
cells after overnight treatment with mevastatin or
vehicle control and subsequent stimulation with
PMA.Experimentwasperformedat three indepen-
dent occasions with similar results; representative
experiment shown ± SD. ***p < 0.005 by t test.
(B and C) Live/Dead Viability/Cytotoxicity staining
to determine viability of MET-producing cells (B),
quantified as percentage dead cells in (C).
(D) Live/Dead BacLight Bacterial Viability staining
to determine viability of FITC-labeled S. aureus
entrapped in the METs produced by RAW cells
after overnight treatment with mevastatin and
subsequent stimulation with PMA. Note that all
trap-forming macrophages as well as entrapped
bacteria are dead, as shown by the red dye
(arrows); nonentrapped bacteria are not stained
by the red dye (green arrow), indicating that they
are alive. See also Figures S3 and S4.
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macrophages capable, upon PMA stimulation, of elaborating
extracellular DNA to form NET-like structures we now refer to
as macrophage extracellular traps (METs). Like NETs, RAW
264.7 METs could be readily visualized with DNA stains such
as DAPI and/or in combination with antibodies against
histone-DNA complexes and were increased 2.2-fold in statin-
treated cells versus controls (Figure 4A). Using mammalian cell
viability staining, we found that formation of METs, as previously
reported for neutrophils and mast cells, is associated with death
of the cell (Figure 4B). The percentage of MET-producing cells
(Figure 4A) correlated well with the percentage of dead cells
(Figure 4C). Using the BacLight LIVE/DEAD viability assay, we
found that the great majority of FITC-labeled S. aureus entrap-
ped within METs were nonviable, as indicated by red staining
(Figure 4D). This finding suggests that, similar to NETs, METs
can subserve an innate immune function. The murine cathelici-
din peptide CRAMP was visualized within MET structures
induced by statin treatment in RAW 264.7 cells (Figure S4A).
Similarly, we found that statin treatment could elicit production
of DNA-based ETs from thioglycolate-elicited murine peritoneal
macrophages (Figure S4B).
Statin Therapy In Vivo Enhances Phagocyte
Bactericidal Activity
To extend our observations to statin treatment of the whole
animal, thioglycolate-stimulated peritoneal cells were extracted
and purified from mice that had been prefed with standard
chow supplemented with or without simvastatin. In both groups
of mice, the composition of the peritoneal cell population was
60%–70% neutrophils and 10%–20% mononuclear cells (Fig-
ure 5A). In good correlation to the in vitro data, the peritoneal
cells from simvastatin-treated mice showed increased produc-
tion of ETs (Figure 5B) as well as enhanced killing of S. aureus
compared to peritoneal cells isolated from control mice
(Figure 5C).448 Cell Host & Microbe 8, 445–454, November 18, 2010 ª2010 ElseProtective Effect of Statin Therapy against
S. aureus Pneumonia
To determine the effects of statin therapy on resistance to
infection, we used an established intranasal inoculation model
of S. aureus pneumonia that has been shown to mirror several
clinical and pathological features of human bacterial pneu-
monia (Bubeck Wardenburg et al., 2007; Bubeck Wardenburg
and Schneewind, 2008). In this model, mice challenged with
a sublethal dose of S. aureus (1–2 3 108 cfu/animal) developed
histopathological evidence of lung organ damage between 24
and 72 hr of infection (Bubeck Wardenburg et al., 2007). In
comparison to mice fed standard chow, we found that mice
fed chow supplemented with simvastatin showed reduced
bacterial levels in the lung 48 hr postchallenge (Figure 5D).
Histopathological changes characteristic of severe bacterial
pneumonia were diminished in simvastatin-treated mice.
Whereas the majority of bronchi and alveolar spaces were oblit-
erated by inflammatory exudates, immune cell infiltrates, and
staphylococci in control mice (Figure 5E, top), the simvasta-
tin-treated group exhibited smaller, discrete areas of inflamma-
tion, surrounded by large unaffected areas of lung tissue (Fig-
ure 5E, bottom). Recruitment of a mixed population of
neutrophils and macrophages was evident in the inflammatory
lesions of both groups. To determine if the effect of statin treat-
ment to enhance ET production was operating in vivo, we also
examined lung sections for ETs. In correlation with our in vitro
data, significantly more ETs (7-fold increase), enriched in
the cathelicidin peptide CRAMP, were found in the simvasta-
tin-treated group (Figures 5F, 5G, S5A, and S5B). Many of the
ETs from simvastatin-treated mice were quite large and
extended into the alveolar space (Figures 5F and S5A), whereas
traps from control mice were small and localized to the alveolar
wall. While the more severe degree of inflammation and pneu-
monia in control mice versus simvastatin-treated mice
precludes a meaningful analysis by total levels, immunofluores-
cence for CRAMP expression on a per cell basis (CRAMP/DAPIvier Inc.
Figure 5. Statin Therapy in Mice Boosts Extracellular Trap Formation Ex Vivo and In Vivo
(A) Cell content (percentage of total cells) of thioglycolate-induced peritoneal cells extracted from mice fed with standard chow or standard chow + simvastatin.
(B) Quantification of NET production by peritoneal cells.
(C) Ex vivo killing of S. aureus strain Newman by thioglycolate-induced peritoneal cells extracted from mice fed with standard chow or standard chow + simvas-
tatin. In (B) and (C): ***p < 0.005 by two-tailed Student’s t-test comparing control versus statin-treated group. Experiments were performed 3or 4 timeswith similar
results; representative experiment shown ± SD.
(D) Recovered bacteria from lungs of mice prefed with standard chow or standard chow supplemented with simvastatin and infected intranasally with 23 108 cfu
S. aureus strain Newman for 48 hr. Data shown are pooled from two independent experiments with n = 10 or n = 7 mice, respectively. *p < 0.05 by two-tailed
Mann-Whitney test.
(E) Representative light micrograph (H&E stained) of lung tissue sections of infected mice prefed with standard chow (control, upper panel) or standard chow
supplemented with simvastatin (lower panel).
(F) Representative fluorescent images of extracellular trap formation (visualized by Alexa 488 green-labeled CRAMP production and counterstained with DAPI) in
paraffin-embedded lung sections of mice prefed with standard chow or standard chow supplemented with simvastatin and intranasally infected with 23 108 cfu
of S. aureus strain Newman for 48 hr.
(G) Quantification of in vivo extracellular trap production visualized in (F). Data are shown as average of six high-power fields (HPF) obtained with a 103/0.3
UPlanFCN objective. **p < 0.01 by two-tailed Student’s t test. See also Figure S5.
Cell Host & Microbe
Statins Boost Phagocyte Extracellular Trapsratio, calculated from the data shown in Figure S5B) was signif-
icantly greater in simvastatin-treated animals (1.01 ± 0.12) than
controls (0.87 + 0.16, p < 0.001).Inhibition of Sterol Production Stimulates the Formation
of Phagocyte Extracellular Traps
We next sought to determine the relationship between the me-
valonate pathway for cholesterol biosynthesis, which statins
target medically, and the observed effect of these drugs to boost
phagocyte antibacterial function. Effective inhibition of HMG-
CoA reductase by siRNA knockdown of Hmgcr in thioglyco-
late-induced murine peritoneal macrophages (Figure 6A) was
sufficient to enhance both their production of METs (Figures
6B and 6C) and their killing of S. aureus (Figure 6D), suggesting
that statin treatment was not exerting an off-target effect.
Moreover, addition of an excess of the downstream HMG-CoA
reductase product mevalonate almost completely blocked the
bactericidal enhancing properties of statin therapy on macro-
phages (1 mM mevalonate shown in Figure 6E; 250 mMmevalo-Cell Host &nate shown in Figure S6A), without exerting a cytotoxic effect on
the cells (Figure S6B).
The mevalonate pathway is involved in a number of cellular
processes, includingproteinprenylationandcholesterol synthesis
(Figure 7A). A critical juncture is the processing of farnesyl pyro-
phosphate (FPP), which can be used in protein prenylation path-
ways, such as farnesylation or geranylgeranylation, or committed
to the cholesterol synthetic pathway by conversion to squalene.
To pinpoint which of these branch pathwaysmediates NET induc-
tion by statins, we performed NET quantitation assays following
treatment with inhibitors against farnesyl transferase (FTI-277),
geranylgeranyl transferase (GGTI-298), and squalene synthase
(YM-53601). We found that YM-53601 induced NETs to a level
similar to mevastatin treatment (Figures 7B and 7C), whereas
GGTI-298 and FTI-277 had no significant effect (Figure 7B). As
observedwith statins, treatment of neutrophils with YM-53601 re-
sulted in enhanced clearance of S. aureus (Figures 7D and 7E).
These data suggest the effects of statins in boosting NET produc-
tion and bacterial killing are mediated by intermediates of the
sterol synthetic pathway.Microbe 8, 445–454, November 18, 2010 ª2010 Elsevier Inc. 449
Figure 6. Statin Induction of Extracellular
Traps Involves HMG-CoA Reductase Inhibi-
tion
(A) Hmgcr transcript expression in thioglycolate-
induced macrophages transfected with Hmgcr
siRNA.
(B) Representative fluorescent images of murine
thioglycolate-induced peritoneal macrophages
following transfection with Hmgcr or control siRNA
forming extracellular traps. MET formation was
visualized in blue (DAPI) and H2A-H2B-DNA
complexes were visualized by Alexa green immu-
nostaining.
(C) Quantification of MET production by murine thi-
oglycolate-induced peritoneal macrophages
following transfection with Hmgcr or control siRNA.
(D) Killing of S. aureus by murine thioglycolate-
induced peritoneal macrophages following trans-
fection with Hmgcr or control siRNA.
(E) Killing of S. aureus by RAW 264.7 cells
following treatment with mevastatin or vehicle
control ± mevalonate. *p < 0.05, **p < 0.01,
***p < 0.005 by two-tailed Student’s t test
comparing control versus statin-treated group.
Experiments were performed 3 or 4 times with
similar results; representative experiment
shown ± SD. See also Figure S6.
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Our results demonstrate that statin treatment to inhibit the sterol
pathway fundamentally alters the innate immune behavior of
phagocytic cells. In response to the leading bacterial pathogen
S. aureus, we found statins to enhance formation of phagocyte
ETs and promote bacterial killing. This phenotypic effect may
function synergistically with cytokine modulation to help explain
human clinical data, pointing to a lower risk of severe bacterial
infection and sepsis in patients receiving statin therapy (Almog
et al., 2007; Kopterides and Falagas, 2009; Kruger et al., 2006;
Liappis et al., 2001; Martin et al., 2007; Thomsen et al., 2008)
and the therapeutic benefits of statins observed in mice
challenged systemically with S. aureus or Salmonella typhimu-
rium (Catron et al., 2004; Chaudhry et al., 2008). The fact that
statins show a protective effect in animals receiving LPS chal-
lenge alone reflects the importance of their immunomodulatory
properties (Ando et al., 2000).
The formation of ETs by phagocytic cells has been shown to
not only exert antibacterial effects but also to provoke inflamma-
tion, and pathological release of ETs appears to play a role in
inflammatory disease conditions such as autoimmune vasculitis
and lupus nephritis (Gupta et al., 2010; Hakkim et al., 2010;
Kessenbrock et al., 2009). In the case of S. aureus, excessive
neutrophil recruitment to the lung, mediated in part by its
secreted a-toxin, is a contributor to lung tissue injury and disease
pathology (Bartlett et al., 2008). It is notable that S. aureus is
capable of triggering the rapid necrotic lysis of neutrophils after
its own phagocytic uptake (Kobayashi et al., 2010). Thus, while
release of NETs in response to S. aureus lung infection may
provoke local inflammation, this calculated ‘‘sacrifice’’ of the
neutrophil could have a more favorable ratio of antibacterial
effect to inflammatory consequences than pathogen-mediated
necrotic neutrophil lysis.450 Cell Host & Microbe 8, 445–454, November 18, 2010 ª2010 ElseBeyond histopathological images of entrapped bacteria,
in vivo evidence that ETs play an important role in innate immu-
nity is derived from studies that show increased virulence of
pathogens capable of producing endonucleases that degrade
ETs (Beiter et al., 2006; Buchanan et al., 2006; Walker et al.,
2007), decreased virulence of bacterial strains expressing
surface structures that promote entrapment within ETs (Crotty
Alexander et al., 2010), or a therapeutic benefit of nuclease
inhibitors in ET preservation at foci of acute infection
(Buchanan et al., 2006). The present study contributes addi-
tional circumstantial evidence for an important role of ETs in
host antibacterial defense and may help explain a decades-
old study that provided clear evidence that an ‘‘as yet uniden-
tified’’ nonphagocytic, extracellular killing mechanism was
critical to control of S. aureus pneumonia in the murine model
(Nugent and Pesanti, 1982). And while our studies confirm
earlier observations that statin therapy inhibits phagocytotic
uptake of bacteria by neutrophils and macrophages (Figures
2A and S3), prior opsonization of the bacteria increased overall
killing by statin-treated neutrophils (Figure 1D), hinting that
other innate antibacterial activities of the phagocytic cells could
be statin responsive. Revealing further complexity and interde-
pendence of extracellular and intracellular killing mechanisms,
prior opsonization and phagocytotic uptake of Candida albi-
cans have each been reported to increase NET production
(Urban et al., 2006).
The ultimate effect of statin induction of ET formation on host
immune clearance of pathogens is certain to vary by bacterial
strain, site of infection, prior immunity of the host, and additional
factors that together merit circumspection in interpreting the
broader implications of our data. Indeed, one report has
described reduced clearance of Klebsiella pneumoniae from
the lung in mice receiving statin treatment (Fessler et al., 2005),
and another report, using assay conditions that would notvier Inc.
Figure 7. Neutrophil Extracellular Trap Induction Involves the Sterol Synthesis Pathway
(A) Diagram of the mevalonate pathway.
(B) NET production following treatment of primary human neutrophils with inhibitors of the mevalonate pathway. ***p < 0.005 by one-way ANOVA with Dunnett’s
post test versus control group.
(C) Representative fluorescent images of NET formation by human primary neutrophils in response to YM-53601 or vehicle control treatment visualized by DAPI
staining.
(D) Killing of S. aureus by human neutrophils following treatment with YM-53601 or vehicle control. ***p < 0.005 by two-tailed Student’s t test comparing control
versus statin-treated group.
(E) Growth of S. aureus strain Newman in RPMI containing YM-53601 (10 mM) or DMSO vehicle control. Experiments were performed 3 or 4 times with similar
results; representative experiment shown ± SD.
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Statins Boost Phagocyte Extracellular Trapssupport ETs, showed reduced opsonophagocytosis of S. aureus
by macrophages and GBS by HL-60 granulocytes after pro-
tracted in vitro treatment with simvastatin (Benati et al., 2010).
Because S. aureus expresses an array of virulence factors that
impair complement-mediated opsonphagocytosis (Jongerius
et al., 2007; Laarman et al., 2010), and because it can resist
oxidative burst killing through catalase expression and the anti-
oxidant golden staphyloxanthin pigment (Liu et al., 2005), the
importance of ET-dependent killing may be proportionately
increased. In contrast, for pathogens highly susceptible to
phagocytosis and subsequent intracellular killing mechanisms,
increased stimulation of phagocytes toward the ET cell death
pathway could prove inconsequential or even detrimental.
Further studies of the relationship between the sterol synthesis
pathways and innate immune function will be important to under-
stand potential infectious disease ramifications for millions of
individuals receiving chronic statin therapy.EXPERIMENTAL PROCEDURES
Animals
Male 10- to 12-week-old CD1 or C57BL/6 mice (Charles River Laboratories;
Wilmington, MA) were used in this study. Mice were maintained under stan-
dard conditions according to institutional guidelines. Experiments were
approved by the UCSD Institutional Animal Care and Use Committee.Cell Host &Bacterial Strains
The bacterial strains used in this study were Staphylococcus aureus strain
Newman, MRSA strain Sanger 252, Streptococcus agalactiae strain COH1,
Salmonella typhimurium strain ATCC13311 and Streptococcus pneumoniae
serotype 2 strain D39. S. aureus, S. typhimurium, and S. agalactiae strains
were grown in Todd-Hewitt broth (THB) at 37C to mid-log phase. S. pneumo-
niae was grown in THB supplemented with 2% yeast extract (Acros; Geel,
Belgium). All bacteria were collected by centrifugation at 9000 rcf for 10 min,
washed once with PBS, and diluted to the required concentration. For
pretreatment of S. aureus with statins, log-phase S. aureus Newman strain
was incubated for 30 min in the presence of 50 mM mevastatin or DMSO
vehicle control. For experiments in which opsonization was used, serum was
collected by spinning fresh human blood at 2000 rpm for 30 min and collecting
serum. For opsonization, log-phase S. aureus was incubated at 37C in the
presence of 5% human serum for 20 min. The bacteria were then harvested
as normal. For growth curve analysis, mid-log-phase S. aureus Newman
was diluted 1:100 in RPMI medium in the presence or absence of 50 mM me-
vastatin (Sigma), 10 mMYM-53601, or vehicle control (DMSO) and incubated at
37C + 5% CO2. Bacterial density (optical density at 600 nm) was measured
hourly.Cell Culture
Human neutrophils were purified from healthy volunteers using the Poly-
morphPrep system (Axis-Shield, Fresenius; Waltham, MA) per manufacturer’s
recommendations. Neutrophils were cultured at 37C+ 5%CO2 in serum-free,
antibiotic-free RPMI at 106 cells/ml (500 ml per well in 24-well plate) in the pres-
ence of 50 mM mevastatin (Sigma), 10 mM simvastatin (Sigma), 10 mM GGTI-
298 (Sigma), 10 mM FTI-277 (Sigma), or 10 mM YM-53601 with appropriateMicrobe 8, 445–454, November 18, 2010 ª2010 Elsevier Inc. 451
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156 ng/ml phorbol myristate acetate (PMA, Sigma) for an additional 1 hr.
RAW 264.7 murine and U937 human monocyte/macrophage cells were
cultured at a density of 106 cells/ml in DMEM and RPMI 1640, respectively,
supplemented with 10% heat-inactivated FBS and penicillin/streptomycin (In-
vitrogen). After 24 hr, cells were further incubated in medium without FBS and
stimulated overnight with 50 mM statin or vehicle control in the presence of
50 mM mevalonolactone (Sigma) to prevent apoptosis and maintain physio-
logic relevance.
In Vitro Bactericidal Assays
Human as well as murine cells were infected with bacteria at a multiplicity of
infection (moi) of 1. After centrifugation for 10min at 1500 rpm, infected neutro-
phils were incubated for 20 min at 37C in 5%CO2. RAW 264.7 and U937 cells
were incubated for 4 and 8 hr, respectively. After incubation, Triton X-100
(0.06% final concentration) was added to lyse infected cells. Lysates were
diluted and plated on THA plates or THA plates supplemented with 2% yeast
extract for enumeration of surviving cfu. Percent killing by statin-treated leuko-
cytes was determined by dividing the number of cfu recovered from statin-
treated neutrophils by the number of cfu from vehicle-treated neutrophils.
Phagocytosis
For determination of phagocytosis by flow cytometry, Alexa Fluor 488-labeled
S. aureuswood strain bioparticles (Invitrogen) were added to cells at amoi of 1.
After 20 min of incubation at 37C, PMNs were washed twice with cold HBSS
(Invitrogen), and mean fluorescence intensity (phagocytosis) was measured
using a FACSCalibur Flow Cytometer (BD Biosciences; San Jose, CA). For
infection of RAWcells, S. aureus bioparticles were added atmoi = 1 and centri-
fuged for 10 min at 1500 rpm. After an additional 10 min of incubation at 37C,
cells were washed twice with cold PBS, detached with trypsin, and washed
again with cold PBS. Again, mean fluorescence intensity (phagocytosis) was
measured using flow cytometry.
Oxidative Burst
After statin treatment, human neutrophils were centrifuged for 5 min at
1600 rpm and resuspended in RPMI 1640 without phenol red (Cellgro; Mana-
ssas, VA). 20,70-dichlorofluorescein (10 mM, Sigma) was then added, and fluo-
rescence was measured using a SpectraMAX Gemini EM fluorescence reader
over the course of 1 hr at 37C. The VMax was calculated by the SpectraMAX
Pro software.
Entrapment Assay
Cells were seeded at a density of 53 105 cells/ml in RPMI and treatedwithme-
vastatin or vehicle control as described above to induce formation of ETs. Cells
were then infected with FITC-labeled S. aureus strain Newman (carboxyfluor-
escein, Invitrogen, 30 min at 4C) at a moi = 20 bacteria per cell. After centri-
fugation for 10 min at 1500 rpm and an additional 5 min of incubation at 37C,
cells were gently washed twice with HBSS to remove unbound bacteria. To
release bacteria from ETs, PMNs were incubated in the presence of 50 U/ml
of DNase I for 15 min at 37C. One hundred microliters of supernatant was
transferred to a 96-well plate. Relative number of bacteria in the supernatant
was determined by reading the absorption/emission at 485 nm/538 nm in
a SpectraMAX Gemini EM fluorescence reader (Molecular Devices; Sunny-
vale, CA).
Induction and Quantification of Extracellular Traps
To induce ETs from human PMNs, PMNs were cultured in serum-free, antibi-
otic-free RPMI at 106 cells/ml in the presence of 50 mM mevastatin (Sigma),
10 mM simvastatin (Sigma), 50 mM lovastatin (Sigma), 50 mM fluvastatin
(Cayman; Ann Arbor, MI), 10 mM GGTI-298 (Sigma), 10 mM FTI-277 (Sigma),
or 10 mM YM-53601 with appropriate concentrations of vehicle control. After
1 hr, cells were stimulated with 156 ng/ml PMA (Sigma) for an additional
1 hr. RAW 264.7 cells were cultured at a density of 105 cells/ml in DMEM
and RPMI 1640, respectively, supplemented with 10% heat-inactivated FBS
and penicillin/streptomycin. After 4 hr, cells were stimulated overnight in
medium without FCS supplemented with statin (50 mM) or vehicle control
and in the presence of mevalonolactone (50 mM, Sigma). To induce METs,
156 ng/ml PMA was added 2 hr prior to analysis. An established method for452 Cell Host & Microbe 8, 445–454, November 18, 2010 ª2010 ElseNET quantification (Fuchs et al., 2007) was adapted for our purposes. Micro-
coccal nuclease (500 mU/ml, Sigma) was added to neutrophils to degrade
ETs. After 15 min of incubation at 37C, 0.5 mM EDTA was added to stop
nuclease activity, and supernatants were collected. Total genomic DNA was
isolated using DNAzol supplemented with polyacryl-carrier (Molecular
Research Center, Inc.; Cincinnati, OH) per manufacturer’s instructions. DNA
was quantified using the PicoGreen dsDNA quantification kit (Invitrogen). Fluo-
rescence wasmeasured using a SpectraMAXGemini EM fluorescence reader.
The percentage extracellular DNA was determined by dividing the amount of
ET DNA by the total DNA. For peritoneal cells, 156 ng/ml PMA was added
1 hr prior to analysis. ET production was assessed using a modified version
of the above ET protocol. Briefly, micrococcal nuclease (500 mU/ml) was
added to neutrophils to release ETs. After 15 min of incubation at 37C,
0.5 mM EDTA was added to stop nuclease activity, and supernatants were
collected. The supernatant was centrifuged for 5 min at 3000 rcf to remove
nonadherent cells. Total genomic DNA was isolated using DNAzol supple-
mented with polyacryl-carrier (Molecular Research Center, Inc.) per manufac-
turer’s instructions. DNA was quantified using the PicoGreen dsDNA quantifi-
cation kit (Invitrogen). Fluorescence was measured using a SpectraMAX
Gemini EM fluorescence reader. The percentage extracellular DNA was deter-
mined by dividing the amount of ET DNA by the total DNA.
Fluorescence Microscopy
For visualization of ETs, cells were seeded on poly-L-lysine-coated glass
slides (neutrophils) or on glass-bottom microtiter plates (macrophages), cell-
type-specifically treated with statins or vehicle control as described above,
infected with S. aureus strain Newman at a moi of 1, centrifuged at 800 rpm
for 10 min, and further incubated for 20 min. The Live/Dead Viability/Cytotox-
icity kit for mammalian cells (Invitrogen) was used without fixation of cells to
visualize NETs or METs and to determine cell viability of trap-forming cells
by fluorescence microscopy. Hoechst-33342-trihydrochloride (final concen-
tration 1 mM) was added to the sample 5 min prior to microscopic analysis
to stain DNA (blue). The Live/Dead BacLight Bacterial Viability Kit (Invitrogen)
was used to determine viability of FITC-labeled S. aureus entrapped in the
METs by fluorescence microscopy. Infected cells were stained as recommen-
ded by the manufacturer using only the red dye component to visualize dead
cells, washed three timeswith PBS, fixedwith 1%paraformaldehyde for 5min,
washed again, and mounted onto glass slides using Prolong Gold (Invitrogen),
amountingmedium that contains the DNA-staining dye DAPI (blue). For immu-
nofluorescence staining of cathelicidin peptides (murine CRAMP or human
LL-37), infected cells were fixed with 4% paraformaldehyde, washed with
PBS, blocked, and permeabilized in the presence of PBS + 3% BSA + 2%
goat serum + 0.2% Triton X-100 for 45 min. Then the samples were washed
again and incubated with polyclonal rabbit anti-CRAMP/LL-37 (diluted
1:300) (Dorschner et al., 2001) or with mouse monoclonal anti H2A-H2B-
DNA complex (#PL2-6 mouse IgG2b stock: 2.65 mg/ml, diluted 1:3000) in
the presence of PBS + 2% BSA overnight at 4C (Losman et al., 1992).
A universal rabbit IgG (Dako; Carpinteria, CA) or mouse IgG2b (Thermo Scien-
tific; Rockford, IL) served as isotype negative control. After washing three
times with PBS, samples were incubated with secondary Alexa 488- or Alexa
568-labeled goat anti-rabbit/mouse IgG antibodies (1:500; Molecular Probes;
Eugene, OR) for 45 min at room temperature, washed again, and embedded
using ProLong Gold with DAPI.
Immunohistopathology
Paraffin-embedded lung tissue samples were deparaffinized by successive
immersion in three changes of xylene for 10 min each and rehydrated by
immersion in decreasing concentrations of ethanol (100%, 95%, and 70%,
each twice for 5 min). After washing with PBS, slides were heated in a micro-
wave for 10 min in the presence of citrate puffer (Dako) for antigen retrieval.
After cooling down for 20 min, the slides were washed with PBS and immuno-
stained as described above. Mounted samples were examined using an in-
verted confocal laser-scanning 2-photon microscope, Olympus FluoView
FV1000 with FluoView Spectral Scanning technology (Olympus; Center Valley,
PA). Images were obtained using a 203/0.7 or 603/1.42 Plan APO objectives.
Alternatively, images were recorded using anOlympus Spinning Disc Confocal
IX81 microscope with a Xenon DG5 illumination source driven by SlideBook
software (Intelligent Imaging Innovations; Denver, CO). In this case, imagesvier Inc.
Cell Host & Microbe
Statins Boost Phagocyte Extracellular Trapswere obtained using a 103/0.3 UPlanFCN, 203/0.45 LUCPlanFLN, or 403/1.0
oil UPlanAPO objective. Mean fluorescence intensities of images were quan-
tified using ImageJ 1.41 software.FACS Analysis
For determination of neutrophil and macrophage content in peritoneal lavage
from thioglycolate-treated mice, cells were incubated for 5 min with anti-CD32
antibodies to block Fc receptors; stained with phycoerythrin (PE)-conjugated
anti-F4/80 (Serotec; Kidlington, UK), fluorescein isothiocyanate (FITC)-conju-
gated anti-Ly6G (Gr1) (BD Pharmingen; San Diego, CA), or with their respec-
tive isotype control antibodies; and incubated for 30 min at 4C. Labeled cells
were analyzed by flow cytometry in a FACSCalibur (Becton Dickinson; Franklin
Lakes, NJ).Ex Vivo Killing Assays
Outbred CD1 mice were fed ad libitum with pulverized Harlan Teklad 7912
chow ± 500 mg/kg simvastatin (generic, pharmaceutical grade from
Dr. Reddy’s Laboratories Ltd. [Hyderabad, India]). After 5 days of feeding,
mice were injected with 3 ml 3% thioglycolate solution (BD Biosciences),
and peritoneal cells were isolated by lavage with PBS 4 hr later. Cells were
treated with 13 RBC lysis buffer (eBioscience; San Diego, CA) to lyse erythro-
cytes, resuspended in RPMI medium, and seeded in tissue culture plates at
a density of 106 cells/ml. Cells were immediately infected with S. aureus strain
Newman using amoi = 1 and then incubated at 37C, 5%CO2 for 30min. After
incubation, Triton X-100 (0.06% final concentration) was added to lyse neutro-
phils, and lysates were plated on THA for enumeration of surviving cfu.Staphylococcus aureus Pneumonia Model
As above, outbred CD1mice were fed ad libitumwith either pulverized chow or
pulverized chow supplemented with 500 mg/kg simvastatin. After 5 days of
feeding, mice were anesthetized with ketamine/xylazine intraperitoneally,
then a sublethal dose of S. aureus strain Newman (1–2 3 108 cfu in 30 ml
PBS) was introduced intranasally to induce pneumonia as previously
described (Bubeck Wardenburg et al., 2007; Bubeck Wardenburg and
Schneewind, 2008). Mice were sacrificed after 2 days, and left lung tissue
was infused and preserved in 10% buffered formalin (Fisher Scientific) for
histological analysis. Right lung tissue was homogenized for 1 min using
zirconia beads (1 mm, BioSpec Products; Bartlesville, OK) in a Mini-Bead-
Beater (BioSpec Products) and plated onto THB agar (THA) plates for over-
night incubation and enumeration of cfu.Lung Histology
Formalin-fixed lung tissue was embedded in paraffin and then cut into 3 mm
thick sections. Tissue sections were stained with hematoxylin and eosin
(H&E) and then examined microscopically for pathological alterations using
a Zeiss Axiolab microscope (Zeiss 103/0.25 Achroplan, 203/0.5 Plan-Neo-
fluor, or 403/0.65 Achroplan objective) with an attached Sony Digital Photo
3CCD-Camera DKC-5000 at calibrated magnifications.siRNA Transfection
To harvest thioglycolate-induced peritoneal macrophages, 12-week-old
C57BL/6 mice were injected intraperitoneally with 3 ml of 3% thioglycolate.
After 3–6 days, macrophages were harvested by peritoneal lavage with PBS
and cultured in RPMI + 10% FBS + penicillin/streptomycin. For killing assays,
macrophages were cultured at 1.43 106 cells/ml. For ET visualization, macro-
phages were cultured at 53 105 cells/ml. Mouse Hmgcr and control SMART-
pool siRNAs (Dharmacon; Lafayette, CO) were transfected into macrophages
using DeliverX tranfection reagent (Panomics; Santa Clara, CA) per manufac-
turers’ instructions. The next day,S. aureus (moi = 1) was added and brought in
close proximity to macrophages by centrifugation. After 8 hr of coincubation,
macrophages were lysed with 0.06% Triton X-100 and plated onto THA plates
for cfu enumeration. Percent killing by Hmgcr siRNA-transfected macro-
phages was determined by dividing the number of cfu recovered from Hmgcr
siRNA-transfected macrophages by the number of cfu from control siRNA-
transfected macrophages.Cell Host &Quantitative RT-PCR
Total RNA was extracted from cells using TRIzol Reagent (Invitrogen). cDNA
was prepared using Superscript III First-Strand Synthesis Supermix for qRT-
PCR (Invitrogen). cDNAs were amplified in SYBR GreenER qPCR SuperMix
(Invitrogen) using an ABI Prism 7100 Sequence Detection System (Applied
Biosystems; Foster City, CA). We used the following primer sequences:
Gapdh-F, 50-AATGTGTCCGTCGTGGATCT-30; Gapdh-R, 50-CATCGAAGGTG
GAAGAGTGG-30; Hmgcr-F, 50-TCGTCATTCATTTCCTCGACAAA-30; Hmgcr-R,
50-GATTGCCATTCCACGAGCTAT-30. Hmgcr sequences were taken from Pri-
merBank (http://pga.mgh.harvard.edu/primerbank/index.html, ID# 18043
195a2). Cycling conditions for PCR amplifications were 15 s at 95C, 25 s an-
nealing at 57C, and 45 s at 72C. Data are expressed as relative mRNA
expression levels normalized to the housekeeping gene Gapdh.
Statistics
Data were analyzed by using GraphPad Prism 4.0 (GraphPad Software; La
Jolla, CA). Each experiment was performed at least three times at independent
occasions, and within each experiment all samples were processed in tripli-
cate. Differences were analyzed using a Student’s t test, a one-way ANOVA,
or a two-tailed Mann-Whitney test; p values < 0.05 were considered
significant.
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